Thalidomide-dexamethasone versus melphalan- prednisolone as first line treatment in elderly patients with multiple myeloma: Second interim analysis

H. Ludwig(Universitätsmedizin Göttingen), Axel Hinke, Miklós Egyed(Somogy Megyei Kaposi Mór Oktató Kórház), Ivan Špıčka(Charles University), Richard Greil(Paracelsus Medical University), Branimir Jakšić(Leeds Teaching Hospitals NHS Trust), Ingrid Kühn, Heinz Gisslinger(Medical University of Vienna), Michael Fridrik, Niklas Zojer(University of Vienna), Martin Mistrík(Radboud University Nijmegen), Roman Hájek(University Hospital Ostrava), Johannes Drach(Vienna General Hospital), Werner Linkesch, Rajko Kušec(University Hospital Dubrava), Boris Labar(Radboud University Nijmegen), E Tóthová
Unknown
January 1, 2007
Cited by 12

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
|The Lancet|2019|636